New guidelines overhaul best practices for heart failure prevention, diagnosis and treatment

Updated heart failure management guidelines add recommendations for the use of SGLT inhibitors and for managing patients with cancer therapy-related cardiotoxicity.

2:00 PM

Author | Haley Otman

heart image lab note navy blue yellow
Michigan Medicine

Clinicians now have an up-to-date, data-driven destination to help them provide the best care possible to their patients with heart failure, thanks to the publication of new clinical practice guidelines from the American College of Cardiology, the American Heart Association and the Heart Failure Society of America.

The new guidelines provide a tremendous resource for physicians who are looking for the latest data to help them care for their patients, given that the last full guideline was published nearly 10 years ago, says Salim Hayek, M.D., an assistant professor of internal medicine and a cardiologist at the University of Michigan Health Frankel Cardiovascular Center, who served on the writing committee.

Physicians who care for patients with heart failure with and without reduced ejection fraction will find new recommendations regarding sodium-glucose cotransporter-2, or SGLT, inhibitors in the guideline.

"This class of drugs, initially meant for treating diabetes, have been shown to be amazing therapies for patients with heart failure," Hayek said. "Most importantly, they work well in patients with heart failure and preserved ejection fraction, a group of patients for which effective treatments are lacking."

Another key message is that heart failure specialty teams, like the Frankel CVC offers, are key to evaluating patients with advanced heart failure and providing life-saving therapies, added guideline writing committee member Monica Colvin, M.D., M.S., associate director of the heart transplant program and an advanced heart failure and transplant cardiologist at the Frankel CVC.

Reducing the prevalence of heart failure to begin with is also given great importance: The heart failure stages are revised to emphasize prevention for people at risk of heart failure or who have pre-heart failure.

In addition, economic analyses are included for some treatments, with value statements to help clinicians and patients who are determining whether to try something expensive. Only one therapy was defined as low-value: tafamidis for cardiac amyloidosis.

And for the first time, the guideline offers recommendations for cardio-oncology, a clinical focus for Hayek, providing guidance on the management and prevention of cancer-therapy related cardiotoxicity.

It's important to note the patient-centric approach of the new guideline, Hayek and Colvin added.

Guideline cited: "2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint 4 Committee on Clinical Practice Guidelines."

More Articles About: Lab Notes Heart Failure Cardiovascular: Preventive Cardiology Cardiovascular: Diseases & Conditions
Health Lab word mark overlaying blue cells
Health Lab

Explore a variety of healthcare news & stories by visiting the Health Lab home page for more articles.

Media Contact Public Relations

Department of Communication at Michigan Medicine

[email protected]


Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Featured News & Stories Adult performs CPR on a young athlete, illustration with red and blue figures
Health Lab
Sudden cardiac arrest in young athletes: 5 things parents should know
Sudden cardiac arrest in young athletes: 5 things parents should know
Provider takes a pulse oximetry reading from a patient's finger
Health Lab
Inaccurate pulse oximeter readings could limit transplants, heart pumps for Black patients with heart failure
Racially biased readings of oxygen levels in the blood using pulse oximeters may further limit opportunities for Black patients with heart failure to receive potentially lifesaving treatments, such as heart pumps and transplants
Illustration of a magenta heart with white plaque on a golden background.
Health Lab
What is heart disease?
Tanuka Piech, M.D., a cardiologist at the University of Michigan Health Frankel Cardiovascular Center, answers questions about heart disease, why we should care and what we can do to help prevent it.
Woman sweating hot flash fan
Health Lab
Menopause and migraines: New findings point to power of prevention
Women who have both migraines and a long-term history of hot flashes and/or night sweats have a slightly higher risk of heart disease and stroke, and young women who have migraines have a higher risk of later persistent menopause symptoms.
A child and her mom play with a toy and in another image, child sits on her bed smiling
Health Lab
Doctors use novel treatment for teen with heart failure
U-M team successfully treats a teen with heart failure using a medication for adults, opening up a potential new therapeutic option for young patients.
News Release
Statewide cardiovascular consortium, hosted at Michigan Medicine, receives national award for patient safety, quality efforts
A collaborative partnership dedicated to improving statewide cardiovascular care and outcomes — hosted at Michigan Medicine — received national recognition for efforts in patient safety and quality. BMC2 received the award for its significant improvements in the documentation of radiation use, a decrease in high-dose radiation exposure and reduction in opioid prescribing rates for patients.